Clinical Trials Browser

INDUSTRY × ceralasertib × Breast × Clear all

NCT03330847 2026-03-10

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

Phase 2 Active not recruiting

273 enrolled 22 charts

Triple Negative Breast Neoplasms